PARP11 interfer(on)es with CAR T cell efficacy

被引：0

作者：

Isabelle Munoz

Paul A. Beavis

机构：

[1] Peter MacCallum Cancer Centre,Cancer Immunology Program

[2] The University of Melbourne,Sir Peter MacCallum Department of Oncology

[3] Parkville,undefined

[4] University of Melbourne,undefined

来源：

Nature Cancer | 2022年 / 3卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Despite the remarkable success of chimeric antigen receptor (CAR) T cell therapies in the treatment of hematological malignancies, this strategy remains challenging in solid tumors. One major obstacle is the hostile immunosuppressive tumor microenvironment. New research demonstrates that targeting PARP11 can overcome this immunosuppression and boost CAR T cell efficacy through stabilization of IFNAR1.

引用

页码：790 / 792

页数：2

共 50 条

[31] Harnessing the Gut Microbiota to Potentiate the Efficacy of CAR T Cell Therapy
Gabrielli, Giulia
Shouval, Roni
Ghilardi, Guido
van den Brink, Marcel
Ruella, Marco
HEMASPHERE, 2023, 7 (09): : E950
[32] RNA Therapeutics for Improving CAR T-cell Safety and Efficacy
Schaible, Philipp
Bethge, Wolfgang
Lengerke, Claudia
Haraszti, Reka Agnes
CANCER RESEARCH, 2023, 83 (03) : 354 - 362
[33] Microscale Methods For Investigating Car T-cell Killing Efficacy
Piscopo, N.
Das, A.
Mueller, K.
Walker, K.
Capitini, C.
Saha, K.
TISSUE ENGINEERING PART A, 2017, 23 : S60 - S60
[34] Identifying the Factors Modulating the Efficacy of CAR-T Cell Therapy
Dolnikov, Alla
Klamer, Guy
Chitranjan, Arjanna
Xu, Ning
Shen, Sylvie
Micklethwaite, Kenneth P.
Lock, Richard B.
O'Brien, Tracey
BLOOD, 2014, 124 (21)
[35] Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy
Pellegrino, Marsha
Del Bufalo, Francesca
De Angelis, Biagio
Quintarelli, Concetta
Caruana, Ignazio
de Billy, Emmanuel
CELLS, 2021, 10 (01) : 1 - 16
[36] IDENTIFYING THE FACTORS MODULATING THE EFFICACY OF CAR-T CELL THERAPY
Dolnikov, A.
Klamer, G.
Shen, S.
Chitranjan, A.
Carol, H.
Lock, R.
O'Brien, T.
CYTOTHERAPY, 2014, 16 (04) : S7 - S7
[37] BOOSTING CAR T CELL EFFICACY BY MODULATION OF THE TUMOR MICROENVIRONMENT IN GLIOBLASTOMA
Mastandrea, I.
Sher, D.
Bayik, D.
Lathia, J.
Friedmann-Morvinski, D.
HUMAN GENE THERAPY, 2022, 33 (7-8) : A10 - A10
[38] The BTLA–HVEM axis restricts CAR T cell efficacy in cancer
Puneeth Guruprasad
Alberto Carturan
Yunlin Zhang
Jong Hyun Cho
Kingsley Gideon Kumashie
Ruchi P. Patel
Ki-Hyun Kim
Jong-Seo Lee
Yoon Lee
Jong Hoon Kim
Junho Chung
Akshita Joshi
Ivan Cohen
Maksim Shestov
Guido Ghilardi
Jaryse Harris
Raymone Pajarillo
Mathew Angelos
Yong Gu Lee
Shan Liu
Jesse Rodriguez
Michael Wang
Hatcher J. Ballard
Aasha Gupta
Ositadimma H. Ugwuanyi
Seok Jae Albert Hong
Audrey C. Bochi-Layec
Christopher T. Sauter
Linhui Chen
Luca Paruzzo
Shane Kammerman
Olga Shestova
Dongfang Liu
Laura A. Vella
Stephen J. Schuster
Jakub Svoboda
Patrizia Porazzi
Marco Ruella
Nature Immunology, 2024, 25 (6) : 1020 - 1032
[39] Antineoplastics/CAR-T cell therapyLack of efficacy: case report
Reactions Weekly, 2022, 1936 (1) : 76 - 76
[40] Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Wu, Huantong
Xu, Zhuofan
Qi, Maoyang
Liu, Penghao
Zhang, Boyan
Wang, Zhenglin
Chen, Ge
Liu, Xiaohai
Liu, Junqi
Wei, Wei
Duan, Wanru
Chen, Zan
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)

← 1 2 3 4 5 →